about
Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the ArtThe angiotensin-converting enzyme insertion/deletion polymorphism and serum levels of angiotensin-converting enzyme in venous thromboembolism. Data from a case control study.Function of platelets in apheresis platelet concentrates and in patient blood after transfusion as assessed by Impact-R.Platelet activation and function during eltrombopag treatment in immune thrombocytopenia.A new measure for in vivo thrombin activity in comparison with in vitro thrombin generation potential in patients with hyper- and hypocoagulabilityCharacterisation of inflammatory response, coagulation, and radiological findings in Katayama fever: a report of three cases at the Medical University of Vienna, AustriaEnzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease.Red cell distribution width and other red blood cell parameters in patients with cancer: association with risk of venous thromboembolism and mortalityBiomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas.Association between the metabolic syndrome, its individual components, and unprovoked venous thromboembolism: results of a patient-level meta-analysisHigh D-dimer levels are associated with poor prognosis in cancer patientsThromboembolic events, bleeding, and drug discontinuation in patients with atrial fibrillation on anticoagulation: a prospective hospital-based registry.Detection of tissue factor-positive extracellular vesicles by laser scanning confocal microscopy.Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI).Cardiovascular risk factors are major determinants of thrombotic risk in patients with the lupus anticoagulant.Alterations of blood coagulation in controlled human malaria infection.Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients.Venous thrombosis and cancer: from mouse models to clinical trials.Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis StudyBiomarkers and venous thromboembolism.Tests predictive of thrombosis in cancer.Treatment and secondary prevention of venous thromboembolism in cancer patients. Current strategies and new therapeutic options.Risk of venous thromboembolism and primary prophylaxis in cancer. Should all patients receive thromboprophylaxis?Biomarkers for prediction of venous thromboembolism in cancer.Platelets in cancer and thrombosis.Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS).VTE risk assessment in cancer. Who needs prophylaxis and who does not?Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants.Venous thromboembolism and vascular access thrombosis in patients with end-stage renal disease on maintenance hemodialysis: Cross-sectional results of the Vienna InVestigation of AtriaL fibrillation and thromboembolism in patients on hemoDIalysis (VEpidemiology and risk factors for venous thromboembolism in lung cancer.Myeloid but not epithelial tissue factor exerts protective anti-inflammatory effects in acid aspiration-induced acute lung injuryOral contraception and menstrual bleeding during treatment of venous thromboembolism: Expert opinion versus current practice: Combined results of a systematic review, expert panel opinion and an international survey.Procoagulant extracellular vesicles in amniotic fluid.Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism.Residual thrombin generation potential is inversely linked to the occurrence of atherothrombotic events in patients with peripheral arterial disease.Platelets and hemophilia: A review of the literature.Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients.Peripheral blood microvesicles secretion is influenced by storage time, temperature, and anticoagulants.Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients.Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment.
P50
Q26776112-E7B95658-0257-4C9B-B0DF-7042A6404B9AQ31133232-7778EEEA-DAB1-458B-AB14-5F7A6C0B1376Q33387718-BA0542D2-2CB4-4872-AA1F-F0A7A95E0564Q33395231-05173665-0742-4D5E-A57B-5B3B5B62A95FQ33599937-6B33E650-6D21-482D-B49F-F5F506B9C87DQ33857976-4866D560-846F-4BD5-8ECF-1C445FA1636EQ33886520-45E9E3FC-1BDC-4131-B44E-90FFBB2079FEQ34408343-90AA58CE-EFEF-4D10-BCA5-9CE9D75B2609Q34511705-78381C94-140B-400E-9E36-D478E1ED0243Q35067214-51FCC013-1C65-4E78-B5B1-F419866AF804Q36133005-43CA54C8-620F-449F-BC79-349AE6AA5BAAQ36219093-F1FF923B-5E50-4167-AD2B-9EBFB5D7A794Q36237425-CEE94C94-0D74-463F-BC92-B6965344304BQ36239524-E1B5B13E-3F9E-40CA-8587-7E4A2E94124FQ36303250-B0CA1CD9-B078-407B-A908-143D58E4AF73Q36443551-30697FC5-0962-42F9-B870-95C384CFB565Q36558396-60659913-01F1-48A5-B7EE-EF60D9EB0398Q36636558-4A8B2BEC-8859-47B8-B5FF-AA34321AD2E8Q37060686-E35235B5-57CC-4AE6-A8FD-E51B02D987E4Q37396646-BFEFC28D-4DEA-4D56-A490-61AF6E82468CQ37740297-8C445F8A-5DC9-494E-97BA-0830CB8D590AQ37913081-73B580DA-9913-4242-B4DB-DB6AC91E4EDDQ37913084-951FC736-B7AC-41CE-9E7D-48F89FC5435FQ38125998-295E4689-A08B-48C7-B6B3-418F7A743621Q38168699-0D88A9A3-3CA8-431E-9276-35A7550BF9CCQ38214965-06345EB4-3DDB-4C0F-B739-8B66D1F96624Q38367713-623CADE5-C786-4B9A-B8BE-2D4837E7D088Q38554324-3A6415AB-3887-419A-8669-9561F15632AEQ38607054-B6AE9DBA-7938-4A74-BD73-100D1E8EB026Q38686784-E0692495-B50B-43FA-8434-1624820685ACQ38783481-CCFB3EA7-1984-411C-BE69-DC7BB74148B7Q38855518-C4E6D8A0-E114-4A95-9D30-9AB8A14EB3A3Q38942810-BDB37835-19C2-4E59-83BA-63AC72A40E5AQ39028469-1BE57E83-A4EF-4788-B350-ABEFACC8C1A8Q39281529-CD26D41E-5420-49C8-8278-96C3192B09E7Q39333812-DA0F7937-D39D-4B7B-B55E-AD59BB06CB41Q39533551-D0A33182-3B85-4FD4-AC49-5C9D7981EEF1Q39575934-93C96463-399E-4B7D-BF4F-6DEF35997F59Q39626842-DE87A54E-DB8A-44D3-BBC2-096DF41E447FQ40217071-5AA24DC2-2565-4232-882C-E7F08AE0EBCD
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究者
@zh
name
Cihan Ay
@ast
Cihan Ay
@en
Cihan Ay
@es
Cihan Ay
@nl
type
label
Cihan Ay
@ast
Cihan Ay
@en
Cihan Ay
@es
Cihan Ay
@nl
prefLabel
Cihan Ay
@ast
Cihan Ay
@en
Cihan Ay
@es
Cihan Ay
@nl
P31
P496
0000-0003-2607-9717